Carregant...
Strategies for Recognizing and Managing Immune‐Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors
The programmed death‐1 (PD‐1) receptor checkpoint inhibitors nivolumab and pembrolizumab represent an important therapeutic advance in the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). Clinical trials have shown substantial therapeutic activity and an acceptable safety profil...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6324643/ https://ncbi.nlm.nih.gov/pubmed/30082490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0045 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|